please click on the headlines below to read the complete article
Two studies highlight retrospective analyses of phase III study of Pomalyst®/Imnovid® (pomalidomide) in previously treated multiple myeloma patients presented at ASH
BOUDRY, Switzerland – (Dec. 10, 2013) – Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that updated analyses from MM-003, the company’s phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination were presented at the American Society of Hematology Annual Meeting in New Orleans, La. Pomalidomide is marketed as POMALYST® in the United States and IMNOVID® in the European Union.
Myeloma canada says new data at this year’s annual ash meeting offers a new standard of care for newly diagnosed multiple myeloma patients
New Orleans, LA, USA and Montreal, Canada, December 9, 2013 –– Findings from a new study show continuous treatment with oral Revlimid® (lenalidomide) plus low-dose dexamethasone (Rd) improves survival and other measures of efficacy, compared to a standard of care for newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant.
pCODR recommends funding lenalidomide (Revlimid) as post-transplant maintenance treatment
Myeloma Canada and the hundreds of patients and caregivers from across the country who provided their personal input to the review process welcome this important decision by pCODR.
Regimen recaptured responses in heavily pretreated multiple myeloma
The combination of panobinostat, bortezomib and dexamethasone recaptured responses in heavily pretreated patients with bortezomib-refractory multiple myeloma, according to results of a phase 2 study.
Cancer researchers discover root cause of multiple myeloma relapse
Clinical researchers at Princess Margaret Cancer Centre have discovered why multiple myeloma, an incurable cancer of the bone marrow, persistently escapes cure by an initially effective treatment that can keep the disease at bay for up to several years.
Health Canada approval expands VELCADE®* indication to include induction treatment in previously untreated multiple myeloma
Janssen Inc. announced today Health Canada’s June 24th approval of the expanded indication for VELCADE®(bortezomib) in the treatment of multiple myeloma, a rare form of blood cancer.
A message from the president.
Over the summer, I began preparatory treatment to have a second autologous Stem Cell Transplant, using my stem cells that had been preserved for over fifteen years.
Health canada approval expands Velcade® indication to include induction treatment in previously untreated multiple myeloma
Janssen Inc. announced today Health Canada’s June 24th approval of the expanded indication for VELCADE® (bortezomib) in the treatment of multiple myeloma, a rare form of blood cancer.
Myeloma Canada Announces Recipient of the 2012 Research Grant
As part of our continuing efforts to advance Canadian myeloma research, Myeloma Canada established the Myeloma Canada research grant in 2011. With guidance from the Myeloma Canada Scientific Advisory Board and the Myeloma Canada Research Network, selection criteria were established to guide the Peer Review Committee in their evaluation and selection process.
Making Myeloma Patients Matter at the 54th Annual Meeting of the American Society of Hematology (ASH)
During ASH, held from December 8th through 11th in Atlanta, Georgia, experts from around the world presented the latest research findings that promise to advance the treatment of blood cancers including multiple myeloma. Myeloma Canada participated in two events with the goal of transforming the scientific data into real-life evidence of how treatment advances have improved survival by having patients share their personal stories.
Thalomid® Approved for Funding in Ontario
Thalomid (thalidomide) is now reimbursed by the Ontario Drug Programs under their Exceptional Access Program (EAP) for the specific eligibility criteria.
Myeloma Canada says Pomalidomide Study Shows Overall Sruvival in Late-Stage Clinical Trial
Clinical studies have shown that an investigational new drug, pomalidomide, has demonstrated overall survival in a clinical trial of myeloma patients who had undergone multiple prior treatments. The international trial that includes several sites in Canada compares pomalidomide plus the steroid dexamethasone to dexamethasone alone.
11 Communities across Canada to Take Part in Multiple Myeloma Marches during Blood Cancer Awareness Month
September 18, 2012 –– This month, people in 11 locations across six provinces will be marching together to “make myeloma matter”. Myeloma, also called multiple myeloma, is a blood cancer that affects cells in the bone marrow. Seven new cases are diagnosed each day in Canada and the disease remains incurable, but new treatments are providing new hope for patients. The Marches will take place on September 23rd and 30th. September is national blood cancer month in Canada.
Myeloma Patients Across Canada to Benefit from New Research Chair
On September 12, 2012 Myeloma Canada, together with Université de Montréal, Maisonneuve-Rosemont Hospital (MRH), Celgene and the MRH Foundation, announced the creation of the Myeloma Canada Chair in Multiple Myeloma Research.
Kyprolis (Carfilzomib): Canadian Update
Kyprolis (carfilzomib), a second generation proteasome inhibitor, was approved by the Food and Drug Administration (FDA) in the United States on July 20th. Onyx Pharmaceuticals, the manufacturer, does not currently have a definite date as to when Kyprolis will be submitted to Health Canada for approval. More information will be made available from the manufacturer over the coming months.
Headway Made Against Multiple Myeloma
For 40 years, there was no improvement in the treatment of multiple myeloma. But over the past 10 years, a host of promising new agents is changing the outlook of the disease. “Finally the goal posts have been moved in myeloma,” said Dr. Andrew Belch, an oncologist/hematologist at the Cross Cancer Institute in Edmonton.
Maintenance Therapy as an Emerging Standard for Improving Survival n Multiple Myeloma
During the last annual meeting of the American Society of Hematology (ASH), Dr Donna Reece of Princess Margaret Hospital in Toronto presented a summary of several trials looking at the role of maintenance therapy following first-line treatment in newly-diagnosed myeloma patients. The report was recently published and has been made available to Myeloma Canada to share with the Canadian myeloma community.
Myeloma Canada Higlights Three Clinically Significant Studies Advancing Myeloma Treatement In the New England Journal of Medicine
Myeloma Canada says three newly published studies demonstrate the value of long-term maintenance treatment with an oral drug Revlimid® in patients with multiple myeloma. Myeloma Canada has previously said that because Revlimid is a self-administered pill, it limits the need for in-hospital treatment, allowing patients to lead more productive lives.
Health Canada Approves Subcutaneous Administration of Velcade® in Multiple Myeloma
Health Canada has approved the subcutaneous (under the skin) administration of Velcade® for multiple myeloma. With this approval, Canadians living with multiple myeloma can now receive a convenient, subcutaneous injection that allows for greater physician and patient treatment choice. This new route of administration may reduce the risk of developing peripheral neuropathy thereby allowing patients to continue their treatment to optimize clinical outcomes.
Zoledronic Acid Significantly Improve Survival Over Clodronate
The use of zoledronic acid for the prevention of skeletal-related events in patients with newly diagnosed multiple myeloma was superior to treatment with clodronate and was found to improve survival even after adjustment for potential effects of skeletal-related events on survival.
To access and read more articles of interest to the myeloma community, please go to news & updates.
Get the PDF version of the myeloma handbook by clicking here...
Get the PDF version of Myeloma Canada Milestones; 2011 Year In Review by
Myeloma Canada is affiliated with the International Myeloma Foundation, the world's oldest and largest myeloma organization
Myeloma Canada gratefully acknowledges the generous unrestricted educational grants from our website sponsors: